Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

Last updated: March 27, 2025
Sponsor: University of Texas Southwestern Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Scleroderma

Treatment

Morphea

Clinical Study ID

NCT01808937
032007021; STU 112010-028
  • Ages < 90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The Morphea in Adults and Children (MAC) cohort is the first registry for both children and adults with morphea (also known as localized scleroderma) in the country. The purpose of the registry is to learn more about morphea, specifically:

  • How morphea behaves over time

  • How frequently specific problems occur along with morphea (for example, arthritis)

  • Whether morphea has an autoimmune background

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patient must have a clinical diagnosis of morphea confirmed by the primaryinvestigator and by histopathological examination.

  2. Ages 0-90 years old

  3. Children must weigh more than 20 lbs. in order to satisfy Children's Medical Centerpolicy for the maximum amount of blood drawn in a 24 hour period.

  4. Patient or legal guardian must be able to speak and read at a 6th grade readinglevel.

  5. Both male and female patients will be eligible

  6. All races and ethnic backgrounds will be included

  7. Relationships to proband: All patients with morphea will be included. A patient'sfamily history will be reviewed and if there is a family history of morphea orsystemic sclerosis then we will give the study patient the investigator's contactinformation and ask the family member to call the study team to answer any questionsand enroll them in the study if they choose to do so.

  8. Ability to give informed consent: Patients must be able to give informed consent orthey will give assent with parent or guardian consent as a minor to be a part of themorphea registry.

Exclusion

Exclusion Criteria:

  • Patients who have been coded as morphea (701.0), but do not have morphea/localizedscleroderma (examples: steroid atrophy, acquired keratoderma, keloids, nephrogenicfibrosing dermopathy, systemic sclerosis, lichen sclerosis)

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: Morphea
Phase:
Study Start date:
May 01, 2007
Estimated Completion Date:
January 31, 2028

Connect with a study center

  • UT Southwestern Medical Center - Department of Dermatology

    Dallas, Texas 75390-9069
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.